Investor Alert: Berger Montague (Canada) PC represents investors in class action against Bausch Health Companies, Inc.

(February 25, 2025). Berger Montague (Canada) PC represents Canadian investors that purchased Bausch Health Companies, Inc.’s (“BHC”) shares listed on the Toronto Stock Exchange. The investors allege that BHC negligently published quarterly investor reports containing misrepresentations about its financial exposures and risks associated with the size of the litigation against by institutional investors that opted-out of the Valeant Pharmaceuticals International, Inc. (n/k/a, Bausch Health Companies, Inc.) shareholder class actions. On April 3, 2023, and May 2, 2024, BHC was forced to disclose that the opt-out litigation survived a motion to dismiss and its motion for summary judgment was largely denied resulting in the share price dropping greater than 20%. 

Having just settled the Valeant class actions and related SEC investigation for over $1 billion, it is obvious that investors would want to the financial risk to BHC prior to investing,” said Andrew Morganti, a member of Berger Montague (Canada) PC. However, the institutional investors that opted-out of the Valeant shareholder class actions are some of the most well-known and proactive institutional investors in the world; and some of them have damage claims for greater than $200 million each with combined damage claims being greater than $4 billion.

Berger Montague (Canada) PC lawyers Andrew Morganti and Vince DeMarco are representing the investors.